Talk:Grail (company)

COI edit requests
Hi! I'm a COI editor posting on behalf of GRAIL, a client of my employer, Porter Novelli. Requesting some updates to this article below. I've also mocked up all the edits here if helpful. There are several items in this request; please let me know if it would be preferable to share in batches rather than all at once and I can do so.


 * Throughout the article: lots of single quotes around phrases that don't seem to need them, e.g. 'Galleri test'. Could these be deleted? Happy to do so myself if helpful.
 * The company was actually established in 2016, not 2015. This needs to be updated in a few places in the article, as well as some categories.
 * The term "liquid biopsy" is used a few times in the article. This may be misleading because Galleri is a screening tool, not a diagnostic; additional follow-up testing is required to confirm the presence of cancer. "Multi-cancer early detection test" would be more accurate.
 * It looks like the consensus is to hyphenate "multi-cancer". Currently, it appears as one word in a few places in this article.
 * Per at the top of the article, converting a few dates throughout the article: 27 November 2020, 31 August 2021, 15 July 2024 and 28 February 2026.

Origin

 * I think it makes sense to update this section title to "History" or "Background" since it covers more than just the company's origin.
 * Delete "Grail's chairman is Jay Flatley."; this is no longer true.
 * Add before "According to Forbes in 2017,":
 * Dr. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, championed the new business and joined its board of directors.


 * Add to end of section: "The company sponsored the Galleri Classic golf tournament in Rancho Mirage, California, in March 2023. "

Galleri test

 * Perhaps this could be broken into "Technology" (currently the first paragraph, explaining how the test works) and "Research" sections (the remaining content, on the studies done on the test).
 * Update "providing information of the origin" to "predicting the origin" for clarity.
 * Add after "The Galleri test detects fragments of DNA in a blood sample via next-generation sequencing, which identifies DNA methylation, distinct patterns of which are associated with particular cancers, potentially allowing early detection of cancer and providing information of the origin of the cancer.":
 * Galleri received breakthrough device designation from the U.S. Food and Drug Administration in May 2019. The test does not diagnose cancer; rather, it detects possible signs of cancer in order to help direct follow-up diagnostic testing. Galleri is not yet approved by the FDA, but it is available by prescription under the agency's provision for laboratory developed tests.


 * Add after "Subsequently the Galleri test entered into a further three trials; STRIVE, SUMMIT, and PATHFINDER studies.":
 * Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer. The study found that the number of cancer detections doubled when multicancer screening was included in the standard of care screening, compared to using only standard screening. The test also predicted the cancer signal origin with 97% accuracy. Of the more than 6,000 participants in PATHFINDER, 35 were diagnosed with cancer, and 71% of those diagnosed were diagnosed with cancer types for which no routine screening is available.


 * Add after "The trial started on 31 August 2021, with primary completion date estimated at 15 July 2024 and study completion on 28 February 2026. ":
 * In a separate NHS trial in collaboration with Oxford University, the SYMPLIFY study is evaluating the test's utility for symptomatic individuals. Initial results shared in June 2023 showed that the test correctly detected two out of three cancers among 5,000 individuals who presented with symptoms. The test also accurately predicted the cancer signal origin in 85% of those cases.


 * Add before "..."
 * In May 2021, Grail announced that Providence Health & Services would be the first health system in the U.S. to offer access to the Galleri test. The next month, the company began selling Galleri tests in the U.S., making it the first commercially available multi-cancer early detection test. Point32Health, parent of Tufts Health Plan and Harvard Pilgrim Health Care, became the first commercial insurance provider to offer the test in November 2022.


 * Add to end of last paragraph:
 * Grail stated that more than half of the people who received erroneous letters had not yet had their blood drawn for the test.

Thank you for your time and consideration! Mary Gaulke (talk) 22:46, 13 July 2023 (UTC)

Reply 15-JUL-2023
Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request. Spintendo 14:04, 15 July 2023 (UTC)

Revised edit request
Hello! Thanks for your review. Dr. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business and joined its board of directors. The test does not diagnose cancer; rather, it detects possible signs of cancer in order to help direct follow-up diagnostic testing. Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer. The study found that the number of cancer detections doubled when multicancer screening was included in the standard of care screening, compared to using only standard screening. The test also predicted the cancer signal origin with 97% accuracy. Of the more than 6,000 participants in PATHFINDER, 35 were diagnosed with cancer, and 71% of those diagnosed were diagnosed with cancer types for which no routine screening is available. In June 2021, the company began selling Galleri tests in the U.S., making it the first commercially available multi-cancer early detection test. Thanks again! Mary Gaulke (talk) 15:41, 26 July 2023 (UTC)
 * Note 1: Some references for the term "multi-cancer early detection test":
 * Note 3: Revised:
 * Note 5: Some references using the term "predict" for cancer signal origin:
 * Note 6: Updated refs:
 * Note 7: Added primary source refs:
 * Note 10: Understood on the partnerships, but I do want to check if this is notable:
 * Thank you for your reply. I'll review this shortly. Regards, Spintendo  19:18, 17 August 2023 (UTC)
 * With regards to Note 1, please specify which of these three references to use. Note 3 has changed "championed" to "advocated" but the underlying question still remains what is meant by this. Note 5, there are 3 references, but it's unclear which of these three to use for the proposed statement. Note 6 was implemented (the Health.com source is not the best I would have hoped for, but it appears to have been "reviewed" by an MD, whatever that means). Note 7 contains a statement which has three references. If all three of these references confirm the information, then only one of them should be supplied (they are all correctly from ESMO, so any one fo them should suffice.) The information following that first sentence can only be implemented after the first sentence's references are settled (so that it reads correctly) Regards, Spintendo  17:33, 21 August 2023 (UTC)
 * Thanks for the review! For what it's worth, I've been advised in the past to provide multiple sources in order to demonstrate the notability of a piece of information and/or to show media consensus around certain terminology. Sounds like I should adjust my best practices.
 * Note 1: Use
 * Note 3: Does this suit better? (Trying not to stray too far from the source material.)
 * Dr. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business, correctly predicting how DNA sequencing technology would make it possible to detect evidence of a tumor from a blood sample. He also joined Grail's board of directors.
 * Note 5: Use
 * Note 7: Revised:
 * Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer. The study found that the number of cancer detections doubled when multicancer screening was included in the standard of care screening, compared to using only standard screening. The test also predicted the cancer signal origin with 97% accuracy. Of the more than 6,000 participants in PATHFINDER, 35 were diagnosed with cancer, and 71% of those diagnosed were diagnosed with cancer types for which no routine screening is available.
 * And following up on Note 10 just in case it was missed, checking if this is notable:
 * In June 2021, the company began selling Galleri tests in the U.S., making it the first commercially available multi-cancer early detection test.
 * Thanks again! Mary Gaulke (talk) 21:38, 21 August 2023 (UTC)
 * Thank you for your reply.
 * Providing multiple sources is good for establishing notability, but it's not necessary for an article's content. For example, if a claim is made in the New York Times, there does not need to be additional sources from industry-related journals and blogs.
 * "and/or to show media consensus around certain terminology" this is also absolutely correct. However, when you say media, what that should mean is reliable, independent, journalistic secondary sources. This ought not to include media covering the industry in question, as these types of media often are providing company-originating information, i.e., press releases and company statements (such as an interview with a company spokesperson/executive which are published verbatim and without any further verification). Those type of statements are easily seen within these sources reading as or  etc. In those instances, the devil is in the details, so to speak.
 * Now the sources you're mentioning above, are these "requested to be added" or "requested to be used" or are they to be deleted? If they are to be added, I would ask in these sources (like the SF Business Times, Genetic Engineering and Biotechnology News, Medical Device Network, and News-Medical.net) are there any instances where the example phrases I've mentioned above are being used in those articles? If they are, even once, then that would be a big clue that these are sources to be avoided. Regards, Spintendo  18:54, 1 September 2023 (UTC)
 * Thanks for the reply!
 * 1. Understood!
 * 2. This also makes sense. That said, I do think consensus across ACS, a medical journal, and a consumer health site indicates that the term "multi-cancer early detection test" is in widespread use, both in reference to Galleri and more generally.
 * 3. I believe my use of the above sources is completely appropriate. Several cite peer reviewed medical studies, and while a few reference the existence of GRAIL statements, they're not connected to the information I'm referencing (e.g. while GEN quotes a GRAIL exec, the information being cited isn't related to the quote; the source is being used to confirm Klausner's appointment to GRAIL's board).
 * Happy to re-compile and post the latest revisions to the requests if helpful. Just let me know. Thank you! Mary Gaulke (talk) 18:54, 12 September 2023 (UTC)

Regarding "multicancer early detection (MCED) test" I see that this is the term already in use in the article, so I'm not understanding what it is you want changed about that. If you have a new request, please feel free to post it under a new level 2 heading at the bottom of the talk page. Regards, Spintendo  20:28, 27 September 2023 (UTC)

Moved page
The page had been at GRAIL (company), Per MOS:TMRULES, we're to use standard case even if the owner prefers ALL CAPS if standard case is commonly used by third parties, and in my quick check of key sources used here like Forbes, Wall Street Journal, Reuters, etc, all used Grail. -- Nat Gertler (talk) 06:57, 18 August 2023 (UTC)

Revised edit requests October 2023
Hello! Updating the above edit requests to reflect all feedback.


 * Delete unnecessary single quotes around 'Galleri test' and other phrases throughout the article.
 * Update the phrase "liquid biopsy" to "multi-cancer early detection test", which is the primary descriptor used for the Galleri test and tests like it in the media.
 * Update "multicancer" (which appears once in the lead and three times in the "Galleri test" section) to "multi-cancer", the standard spelling in most media.
 * Rename the "Origin" section to "History" since it covers more than the company's origin.
 * In the "Origin" section, add before "According to Forbes in 2017,":
 * Dr. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business, correctly predicting how DNA sequencing technology would make it possible to detect evidence of a tumor from a blood sample. He also joined Grail's board of directors.


 * In the "Galleri test" section, update "providing information of the origin" to "predicting the origin". This phrase should also be updated in the lead.
 * Add after "Galleri received breakthrough device designation from the U.S. Food and Drug Administration in May 2019. ":
 * The test does not diagnose cancer; rather, it detects possible signs of cancer in order to help direct follow-up diagnostic testing.


 * Add after "Subsequently the Galleri test entered into a further three trials; STRIVE, SUMMIT, and PATHFINDER studies.":
 * Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer. The study found that the number of cancer detections doubled when multicancer screening was included in the standard of care screening, compared to using only standard screening. The test also predicted the cancer signal origin with 97% accuracy. Of the more than 6,000 participants in PATHFINDER, 35 were diagnosed with cancer, and 71% of those diagnosed were diagnosed with cancer types for which no routine screening is available.


 * Add before "As of January 2023..."
 * In June 2021, the company began selling Galleri tests in the U.S., making it the first commercially available multi-cancer early detection test.

Thanks for your help! Mary Gaulke (talk) 12:10, 4 October 2023 (UTC)


 * @MaryGaulke Thank you for both reducing the number of excess references and for clarifying which changes are to be made. One final question, with regards to the Nicholson et.al and the Sasieni et.al sources, the first gives pages 733-743 and the second gives pages 72-80, are those the pages that the entire report exists on, or are those the pages were the actual information claimed in the proposed text exists? It seems like a lot of pages if it's the latter. Please advise. Thanks! Regards, Spintendo  16:30, 4 October 2023 (UTC)
 * Hello! Confirming it's the former – those are the pages on which the reports appear. Please let me know if I should revise somehow. Thanks! Mary Gaulke (talk) 16:52, 4 October 2023 (UTC)
 * Thank you for the clarification. If you could revise the pages parameter of the citation so that it displays only the pages where the sourced information appears, that would be most helpful. Thank you! Regards, Spintendo  19:23, 4 October 2023 (UTC)
 * No problem. This is updated above! Mary Gaulke (talk) 20:12, 4 October 2023 (UTC)

Reply 7-OCT-2023
Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.

Regards, Spintendo  22:49, 7 October 2023 (UTC)

Revised edit requests October 2023 v.2
Hi again – following up on just a few items from above per the feedback received.
 * In the "History" section, add before "According to Forbes in 2017,":
 * Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business. According to the San Francisco Business Times, he correctly predicted how DNA sequencing technology would make it possible to detect evidence of a tumor from a blood sample. He also joined Grail's board of directors.


 * Add after "Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer. ":
 * Additionally, the test predicted the cancer signal origin with 97% accuracy.

Thanks for your assistance. Mary Gaulke (talk) 15:15, 18 October 2023 (UTC)

Reply 18-OCT-2023
Regards, Spintendo  21:39, 18 October 2023 (UTC)
 * 1) ✅ The information concerning Klausner was added to the indicated section.
 * 2) ❌ The information concerning PATHFINDER was not added because clear directions for the text's emplacement were not given (e.g., Add after "Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer. "add after" does not state after what).
 * Hi! To be clear, on point 2 above, the text you quoted is the text after which the new text should be inserted. The new text (i.e. "Additionally, the test predicted the cancer signal origin with 97% accuracy. ") is on the following line. Thank you! Mary Gaulke (talk) 20:07, 23 October 2023 (UTC)
 * To be clear, the text you quoted is the text after which the new text should be inserted. I'm afraid it's not at all clear. Edit requests should ideally contain only what is being added or removed. Anything that "carries over" should not be here. If the text that I quoted is the text after which the new text is to be inserted, then why is this text (after which the new text is to be inserted) in your request? Needless to say, you and I could re-enact what appears to be our own version of Who's on First? all day long   but it would really just be quicker to submit a new request. Thank you! Regards,  Spintendo  03:34, 3 November 2023 (UTC)

Edit request Nov 2023
Hi! Just a quick request:

Add the below text to the end of the second paragraph of the "Galleri test" section, after "...43.1% positive predictive value for the detection of early-stage cancer. ":
 * Additionally, the test predicted the cancer signal origin with 97% accuracy.

Thank you! Mary Gaulke (talk) 18:05, 3 November 2023 (UTC)
 * The URL connected to this source doesn't appear to be functioning. This is what displays when following the link:


 * So I'm afraid there is not much I can do with this request.
 * Regards, Spintendo  23:18, 3 November 2023 (UTC)

Edit request Nov 2023 v.2
Hi again! The reference URL for the previous request went down after I posted it, so reposting with an updated link:

Add the below text to the end of the second paragraph of the "Galleri test" section, after "...43.1% positive predictive value for the detection of early-stage cancer. ":
 * Additionally, the test predicted the cancer signal origin with 97% accuracy.

Thank you! Mary Gaulke (talk) 17:55, 14 November 2023 (UTC)


 * ✅ The phrasing that I used for this was the following: "Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer, with the test predicting the cancer signal origin with 97% accuracy in less than three months' time. as per the source. Regards, Spintendo  22:07, 14 November 2023 (UTC)

April 2024 COI edit requests
Hi! As noted above, I'm a COI editor for Grail. Requesting some updates to this article.


 * Add to end of second paragraph of "Galleri test" section:
 * Comprehensive prospective trial data published in The Lancet in October 2023 provided additional detail; of the 6,662 participants, 92 received a "cancer signal detected" result, and 35 were diagnosed with cancer. The median time between result and diagnostic resolution was 79 days.


 * In "Galleri test" section, add after "The trial started on August 31, 2021, with primary completion date estimated at July 15, 2024, and study completion on February 28, 2026.":
 * SYMPLIFY, a separate NHS study led by the University of Oxford, evaluated the test's utility for symptomatic individuals. Results published in The Lancet Oncology in June 2023 showed that the test had a positive predictive value of 75.5% and accurately predicted where a cancer signal came from in 85.2% of cases in which a cancer signal was detected in participants with cancer.


 * Add to end of "Galleri test" section:
 * Grail partnered with the Whitman-Walker Institute and the Cancer Support Community on a study to assess Galleri's real-world feasibility in September 2023. In November 2023, Grail initiated an investigational device exemption study to evaluate Galleri in up to 50,000 Medicare beneficiaries. The study, called REACH (Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity), focuses particularly on historically underserved racial and ethnic minorities.


 * Add a top-level "Recognition" section as follows:
 * Time listed Galleri among the 200 best inventions of 2022. In 2023, Grail ranked #32 on the Fortune Change the World list of 59 companies addressing global challenges.

Thank you for your help! Mary Gaulke (talk) 18:49, 11 April 2024 (UTC)


 * Hi! Adding on two more requests for this article to reflect recent news.
 * Update the "name" parameter in the infobox to "GRAIL, Inc."
 * At the end of "History", update
 * The European Commission (EC) has since approved Illumina's divestment plan for separating from Grail. Illumina has set a goal of finalizing the divestment terms by the end of the second quarter of 2024. In April 2024, the EC approved Illumina's plan, allowing Illumina to explore either a trade sale or a capital markets transaction (spin-off) to divest Grail. In May 2024, Illumina publicly filed a Form 10 registration statement with the U.S. SEC, a necessary step for a potential capital markets separation of Grail. If a capital markets transaction occurs, Illumina must capitalize Grail with around $1 billion to fund 2.5 years of operations per the EC's divestment plan.
 * to
 * Illumina completed its spinoff of Grail in June 2024, and Grail began trading on the Nasdaq with ticker symbol GRAL. Illumina retained a 14.5% share of Grail.
 * Thank you! Mary Gaulke (talk) 18:37, 8 July 2024 (UTC)
 * Thank you! Mary Gaulke (talk) 18:37, 8 July 2024 (UTC)